Consultancy
Keytruda LoE: A seismic shift for oncology?
Immune checkpoint inhibitors (ICIs) have changed the face of oncology treatment since their initial entry in the early 2010s. Driven mostly by the group of PD-1 and PD-L1 molecules, they have resulted in cumulative 2023 global revenues exceeding $45 billion USD. Within the PD-...
Enhancing Data Governance with Secure Data Environment Portals
Join us to explore the Thames Valley and Surrey Secure Data Environment (SDE) and how the innovative Mauro solution, developed in collaboration between Oxford University (OU), Oxford University Hospital (OUH) and System C, is supporting the SDE in streamlining data governance and securi...
Practical Essentials of Sample Preparation Course | 16th - 19th December 2024
Join our 4-day virtual course scheduled for 16th - 19th December, 2024
Join Anthias Consulting's Applied Interpretation of LC-MS Mass Spectra Course
This course on 2nd - 4th December 2024, is an introduction to mass spectral interpretation presenting the fundamental tools and rules when interpreting full-scan LC-MS data. You will benefit from a greater understanding of how to interpret the mass spectra produced by Electrospray Ionis...
Comprehensive GC Software (Shimadzu)
Join our 2-day virtual classroom on 2nd & 3rd December, 2024 (£1050*)
Cambridgeshire and East Anglia companies in Deloitte UK Tech Fast 50 ranking
In a ranking of the UK’s 50 fastest growing technology companies, Halo Service Solutions and bit.bio secure places For a second year running, online blanking platform Allica Bank has topped the UK ranking; ...
Strategies for combination therapy in oncology – Part three: Thinking outside the box
This article is published in PM360
The economic cost of living with a rare disease across Europe
Although rare diseases affect a relatively small number of patients, collectively there are an estimated 30 million people in Europe living with 6,000-7,000 known rare diseases (RDs). There is growing recognition of rare diseases as a public health concern, given the many social, mental...
Price achieved for first indication vs. ASMR
CRA Life Sciences continues its series on leveraging RADAR, its orphan drug data repository, with a focus on PMA trends between ASMR outcomes and average annual treatment costs. The analysis shows a clear correlation between the ASMR rating and the level of price achieved. Notably, ASMR...
Improving patient access to medicines targeting early-stage cancers in Europe
This article was published in ISPOR Value and Outcomes Spotlight